Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

Trial Profile

A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2018

At a glance

  • Drugs Nemonoxacin (Primary) ; Moxifloxacin
  • Indications Community-acquired pneumonia; Diabetic foot ulcer; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 23 May 2018 Results (n=48) assessing the effects of nemonoxacin on ECG-measured QT/QTc interval in the fasted and fed conditions and find relationships between QT/QTc and drug absorption, were published in the Clinical Therapeutics.
    • 08 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top